Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365689 | 0.93 | CSNK2A1 (0.44) | CSNK2A1CYP2A6GPR84 | |
| SCHEMBL30408342 | 0.85 | CSNK2A1 (0.44) | CSNK2A1KDM1AKDM1BCYP2A6KCNH2 | |
| SCHEMBL14810674 | 0.85 | CSNK2A1 (0.44) | CSNK2A1KDM1AKDM1BCYP2A6KCNH2 | |
| SCHEMBL3366188 | 0.84 | CSNK2A1 (0.42) | CSNK2A1 | |
| SCHEMBL29257625 | 0.82 | CSNK2A1 (0.37) | CSNK2A1KDM1AKDM1BCYP2A6GPR84 | |
| SCHEMBL696046 | 0.82 | CSNK2A1 (0.37) | CSNK2A1KDM1AKDM1BCYP2A6GPR84 | |
| SCHEMBL24384654 | 0.78 | CSNK2A1 (0.44) | CSNK2A1KDM1AKDM1BCYP2A6 | |
| SCHEMBL13405938 | 0.77 | CSNK2A1 (0.48) | CSNK2A1CYP2A6 | |
| SCHEMBL3363763 | 0.76 | KDM1A (0.38) | KDM1AKDM1BGPR84HTR2ASLC6A4 | |
| SCHEMBL18932097 | 0.75 | CSNK2A1 (0.47) | CSNK2A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2134720-B1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| CN-101711252-A | heterocyclic spiro-compounds | NOVARTIS AG | 2010-05-19 | — | — | CN | disclosed |
| EP-2134720-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | Novartis Ag (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008119744-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | CSNK2A1 1542/4885KDM1A 3591/4885KDM1B 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.